151 related articles for article (PubMed ID: 37339170)
1. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133.
Keats MA; Han JJW; Lee YH; Lee CS; Luo J
Cancer Res; 2023 Sep; 83(17):2816-2823. PubMed ID: 37339170
[TBL] [Abstract][Full Text] [Related]
2. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
3. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
Wei D; Wang L; Zuo X; Maitra A; Bresalier RS
Clin Cancer Res; 2024 Feb; 30(4):655-662. PubMed ID: 37831007
[TBL] [Abstract][Full Text] [Related]
4. KRAS inhibitors: going noncovalent.
Drosten M; Barbacid M
Mol Oncol; 2022 Dec; 16(22):3911-3915. PubMed ID: 36383067
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
[TBL] [Abstract][Full Text] [Related]
6. Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS
Feng J; Hu Z; Xia X; Liu X; Lian Z; Wang H; Wang L; Wang C; Zhang X; Pang X
Oncogene; 2023 May; 42(20):1620-1633. PubMed ID: 37020035
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma.
Gulay KCM; Zhang X; Pantazopoulou V; Patel J; Esparza E; Pran Babu DS; Ogawa S; Weitz J; Ng I; Mose ES; Pu M; Engle DD; Lowy AM; Tiriac H
Cancer Res; 2023 Sep; 83(18):3001-3012. PubMed ID: 37378556
[TBL] [Abstract][Full Text] [Related]
8. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor efficacy of a potent and selective non-covalent KRAS
Hallin J; Bowcut V; Calinisan A; Briere DM; Hargis L; Engstrom LD; Laguer J; Medwid J; Vanderpool D; Lifset E; Trinh D; Hoffman N; Wang X; David Lawson J; Gunn RJ; Smith CR; Thomas NC; Martinson M; Bergstrom A; Sullivan F; Bouhana K; Winski S; He L; Fernandez-Banet J; Pavlicek A; Haling JR; Rahbaek L; Marx MA; Olson P; Christensen JG
Nat Med; 2022 Oct; 28(10):2171-2182. PubMed ID: 36216931
[TBL] [Abstract][Full Text] [Related]
10. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
[TBL] [Abstract][Full Text] [Related]
12. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Kemp SB; Cheng N; Markosyan N; Sor R; Kim IK; Hallin J; Shoush J; Quinones L; Brown NV; Bassett JB; Joshi N; Yuan S; Smith M; Vostrejs WP; Perez-Vale KZ; Kahn B; Mo F; Donahue TR; Radu CG; Clendenin C; Christensen JG; Vonderheide RH; Stanger BZ
Cancer Discov; 2023 Feb; 13(2):298-311. PubMed ID: 36472553
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS
Orsburn BC
J Proteome Res; 2023 Dec; 22(12):3703-3713. PubMed ID: 37983312
[TBL] [Abstract][Full Text] [Related]
15. KRAS
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Paradiso F; Sugimoto H; Arian KA; Ying H; Barekatain Y; Sthanam LK; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
Cancer Cell; 2023 Sep; 41(9):1606-1620.e8. PubMed ID: 37625401
[TBL] [Abstract][Full Text] [Related]
16. Site-specific mutagenesis screening in KRAS
Choi J; Shin JY; Kim TK; Kim K; Kim J; Jeon E; Park J; Han YD; Kim KA; Sim T; Kim HK; Kim HS
Cancer Lett; 2024 Jun; 591():216904. PubMed ID: 38642608
[TBL] [Abstract][Full Text] [Related]
17. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
18. The KRAS
Nat Med; 2022 Oct; 28(10):2017-2018. PubMed ID: 36207523
[No Abstract] [Full Text] [Related]
19. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
